|
|
Post by mango on Feb 25, 2020 11:35:24 GMT -5
I personally believe this was a tremendously wise and good call by Mike. It is significantly better to narrow the focus than being all over the place with no real objectives/visions.
These two new areas of focus going forward is part of the new branding mission as well.
I am very excited that MannKind will be internally focusing on just these two broad areas, while also still being open to out-licensing Technosphere to other companies for drugs with indications outside these two areas of focus.
What are ya'lls thoughts?
|
|
|
|
Post by peppy on Feb 25, 2020 12:04:44 GMT -5
I personally believe this was a tremendously wise and good call by Mike. It is significantly better to narrow the focus than being all over the place with no real objectives/visions. M These two new areas of focus going forward is part of the new branding mission as well. I am very excited that MannKind will be internally focusing on just these two broad areas, while also still being open to out-licensing Technosphere to other companies for drugs with indications outside these two areas of focus. What are ya'lls thoughts? Thoughts. The rebranding. The first thing Mike talked about was rebranding. www.mannkindcorp.com Then he talked about the Corona virus and no impact on MNKD business. Then He talked about;  |
|
|
|
Post by mango on Feb 25, 2020 12:08:13 GMT -5
I personally believe this was a tremendously wise and good call by Mike. It is significantly better to narrow the focus than being all over the place with no real objectives/visions. M These two new areas of focus going forward is part of the new branding mission as well. I am very excited that MannKind will be internally focusing on just these two broad areas, while also still being open to out-licensing Technosphere to other companies for drugs with indications outside these two areas of focus. What are ya'lls thoughts? Thoughts. The rebranding. The first thing Mike talked about was rebranding. www.mannkindcorp.comThen he talked about the Corona virus and no impact on MNKD business. Then He talked about; What are your thoughts on this? |
|
|
|
Post by peppy on Feb 25, 2020 12:19:38 GMT -5
I would like to make life more humann.
|
|
|
|
Post by mango on Feb 25, 2020 12:20:30 GMT -5
I would like to make life more humann. Awwwwwww yeeeaaahhhh. |
|
|
|
Post by rfogel on Feb 25, 2020 12:21:01 GMT -5
What are the "two pipeline compounds in orphan lung diseases"? I'm afraid I can't find their pipeline on their new website.
|
|
|
|
Post by peppy on Feb 25, 2020 12:22:02 GMT -5
|
|
|
|
Post by mango on Feb 25, 2020 12:30:46 GMT -5
What are the "two pipeline compounds in orphan lung diseases"? I'm afraid I can't find their pipeline on their new website. Dornase alpha and Tobramycin. |
|
|
|
Post by ktim on Feb 25, 2020 17:55:47 GMT -5
Given that they don't have money to do advertising for their current one and only product Afrezza, it seems a long time before they would be able to put any money behind this effort to do corporate branding... but the concept looks nice. I assume for the foreseeable future this branding will just be for investor consumption via corporate website, CC and investor conferences.
|
|
|
|
Post by mango on Feb 25, 2020 18:33:42 GMT -5
Given that they don't have money to do advertising for their current one and only product Afrezza, it seems a long time before they would be able to put any money behind this effort to do corporate branding... but the concept looks nice. I assume for the foreseeable future this branding will just be for investor consumption via corporate website, CC and investor conferences. Corporate branding would be branding the name of the company, correct? The new brand is a service, hence the "life more humann" is a service mark and not a trademark. They would therefore be branding a service, and not a campaign to brand the name, MannKind. |
|
|
|
Post by sayhey24 on Feb 25, 2020 18:49:29 GMT -5
Mango - think of the irony. Didn't many tell us how Technosphere was going to destroy the lungs? I can remember a longtime poster here telling us a few years back in not so many words that his endo would not prescribe afrezza because it would make his lungs explode.
Now MNKD's focus is orphan lung diseases, thats brilliant. As long as Mike figures out how to sell afrezza with all the great data Dr. Kendall just presented I will be happy.
I am not happy they could not figure out a way to get the Libre approved for the India study. I had hoped it was a done deal.
I am also hoping in addition to endocrinology and orphan lung diseases, we hear some great news on RLS.
|
|
|
|
Post by ktim on Feb 25, 2020 19:08:01 GMT -5
Given that they don't have money to do advertising for their current one and only product Afrezza, it seems a long time before they would be able to put any money behind this effort to do corporate branding... but the concept looks nice. I assume for the foreseeable future this branding will just be for investor consumption via corporate website, CC and investor conferences. Corporate branding would be branding the name of the company, correct? The new brand is a service, hence the "life more humann" is a service mark and not a trademark. They would therefore be branding a service, and not a campaign to brand the name, MannKind. Companies that only sell services would presumably have service marks for their corporate branding. I actually wouldn't know what a company that provides both products and services would do with their corporate branding... maybe you just pick one, or perhaps you file for both a service and trade mark on the same name/logo? The only service that Mannkind seems to have currently is the R&D services they provide related to their partnerships. The use of this new "humann" so far is limited to the corporate site and not being used in conjunction with Afrezza marketing (at least not afrezza.com, which is the only Afrezza marketing I'm aware of currently). Whatever, the basic message I think is valid, that we can't even afford to advertise for Afrezza, much less this if it is unrelated. |
|
|
|
Post by ktim on Feb 25, 2020 19:23:59 GMT -5
Mango - think of the irony. Didn't many tell us how Technosphere was going to destroy the lungs? I can remember a longtime poster here telling us a few years back in not so many words that his endo would not prescribe afrezza because it would make his lungs explode.
Now MNKD's focus is orphan lung diseases, thats brilliant. As long as Mike figures out how to sell afrezza with all the great data Dr. Kendall just presented I will be happy. I am not happy they could not figure out a way to get the Libre approved for the India study. I had hoped it was a done deal. I am also hoping in addition to endocrinology and orphan lung diseases, we hear some great news on RLS. I don't remember that, but do you think he was serious or simply using sarcasm/hyperbole to characterize an endo's refusal to prescribe over safety concerns? There have been numerous patients on social media saying endos have raised long term lung safety as reason to not prescribe, though I can't imagine any doctor (or anyone else) saying a lung can explode and being serious about it. As for RLS, the next news we'll hear (if we ever do) should be announcement or filing regarding Phase 1 trial. I guess I wouldn't view that as inherently "great", but I suppose if you're looking at what you think is your friends corpse and then he gasps that indeed would be "great". |
|
|
|
Post by golfeveryday on Feb 25, 2020 19:29:31 GMT -5
Thoughts. The rebranding. The first thing Mike talked about was rebranding. www.mannkindcorp.comThen he talked about the Corona virus and no impact on MNKD business. Then He talked about; What are your thoughts on this? has uthr buy in written all over it |
|
|
|
Post by agedhippie on Feb 25, 2020 23:03:38 GMT -5
Mango - think of the irony. Didn't many tell us how Technosphere was going to destroy the lungs? I can remember a longtime poster here telling us a few years back in not so many words that his endo would not prescribe afrezza because it would make his lungs explode. ... "Making people's lungs explode" was your invention, credit where credit is due. What my endo actually said was that they thought they saw fibrosis in the lungs linked to Exubera and they were concerned that Afrezza might behave the same. You pumped it as exploding lungs for shock value, not because he said it. |
|
